<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05090202</url>
  </required_header>
  <id_info>
    <org_study_id>diabetes and heart failure</org_study_id>
    <nct_id>NCT05090202</nct_id>
  </id_info>
  <brief_title>Prediabetes and Newly Diagnosed Diabetes in Chronic Heart Failure</brief_title>
  <official_title>Prevalence of Prediabetes and Newly Diagnosed Diabetes in Patients With HFpEF( Heart Failure With Preserved Ejection Fraction) and HFrEF(Heart Failure With Reduced Ejection Fraction) in Sohag University Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim the study is to determine the prevalence of prediabetic dysglycemia and newly&#xD;
      diagnosed diabetes among individuals with CHF(chronic heart failure) in sohag university&#xD;
      hospital patients .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      - Prospective study to:&#xD;
&#xD;
        1. study the differences in the prevalence of Prediabetes and newly diagnosed diabetes&#xD;
           among the patients with HFrEF and HFpEF&#xD;
&#xD;
        2. The effect of dysglycemia on prognosis of patients with chronic heart failure.&#xD;
&#xD;
        3. The effect of early discover of diabetes mellitus on prognosis of patients with chronic&#xD;
           heart failure&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 18, 2021</start_date>
  <completion_date type="Anticipated">March 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 8, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Heart failure hospitalization.</measure>
    <time_frame>From date of randomization up to 1 month</time_frame>
    <description>Heart failure hospitalization or cardiovascular (CV) death, and all-cause death, and estimated hazard ratios (HR) by use of multivariable Cox regression models.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>HFrEF &quot; Heart failure with reduced ejection fraction&quot;</arm_group_label>
    <description>chronic heart failure with echocardiographic finding of LVEF &quot;Left ventricular ejection fraction&quot; equal or less than 40%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFmrEF &quot;Heart failure with mildly reduced ejection fraction&quot;</arm_group_label>
    <description>chronic heart failure with echocardiographic finding of LVEF between 41% and 49%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFpEF &quot; Heart failure with preserved ejection fraction&quot;</arm_group_label>
    <description>chronic heart failure with echocardiographic finding of LVEF equal or more than 50%</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>hbA1C</intervention_name>
    <description>hbA1C will be measured for all patients and results will be analysed into Non diabetic, Prediabetic and Diabetic</description>
    <arm_group_label>HFmrEF &quot;Heart failure with mildly reduced ejection fraction&quot;</arm_group_label>
    <arm_group_label>HFpEF &quot; Heart failure with preserved ejection fraction&quot;</arm_group_label>
    <arm_group_label>HFrEF &quot; Heart failure with reduced ejection fraction&quot;</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients presented by heart failure NYHA class 2 or more and admitted to Sohag&#xD;
        University hospital according to inclusion and exclusion criterea&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  All patients presented by heart failure&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Classified according to NYHA &quot; New York Heart Association&quot; classification from NYHA&#xD;
             class 2 and more&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Overt diabetes&#xD;
&#xD;
          -  Rheumatic Heart Disease&#xD;
&#xD;
          -  Congenital heart disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Heba S AbdelKader</last_name>
    <phone>01067892227</phone>
    <email>heba011214@med.sohag.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hassan A Hasanien, prof</last_name>
    <phone>01003459741</phone>
  </overall_contact_backup>
  <reference>
    <citation>Nielsen R, Jorsal A, Iversen P, Tolbod L, Bouchelouche K, Sørensen J, Harms HJ, Flyvbjerg A, Bøtker HE, Wiggers H. Heart failure patients with prediabetes and newly diagnosed diabetes display abnormalities in myocardial metabolism. J Nucl Cardiol. 2018 Feb;25(1):169-176. doi: 10.1007/s12350-016-0622-0. Epub 2016 Jul 29.</citation>
    <PMID>27473218</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Heba Saber AbdelKader</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

